Reported 3 days ago
Novo Nordisk's shares increased following a Financial Times report indicating that activist investor Parvus Asset Management is acquiring shares to influence the hiring of the company's next CEO. Despite a nearly 8% decline since the year's start and slowing sales growth for its weight-loss drugs Ozempic and Wegovy, the stock received a boost amidst the news. Novo Nordisk's current CEO is set to depart once a successor is found.
Source: YAHOO